Evolus, Inc. (NASDAQ: EOLS) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $443M. The Maz Rating grades it against the other companies in its sector.
Evolus, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.69, Evolus, Inc. trades at 1.4x sales. Over the last twelve months it generated about $327M of revenue and a net loss of $31M. It runs a gross margin of 65.9%, an operating margin of -5.7% and a net margin of -9.6%. It shows return on equity of 103.2%, return on invested capital of -12.8% and a free cash flow yield of -1.7%. On the balance sheet: a debt-to-equity ratio of -4.38 and a current ratio of 1.42. Over the past 52 weeks the share price ranged from $3.86 to $9.31, with a beta of 1.34.
Evolus, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 11 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Evolus, Inc. (EOLS) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 30.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.09% / 30% · Interest income / Revenue 0.38% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 30.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.09% / 33% · Receivables / Mkt Cap (36m) 11.7% / 49% · Interest income / Revenue 0.38% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 30.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.09% / 33.33% · Receivables / Mkt Cap (24m) 11.7% / 33.33% · Interest income / Revenue 0.38% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 63.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 19.5% / 33.33% · Receivables / Avg Assets (4Q) 23.5% / 33.33% · Interest income / Revenue 0.38% / 5% | Fail |
| FTSE | Debt / Total Assets 55.3% / 33.33% · (Cash+ST Inv) / Total Assets 14.7% / 33.33% · (Cash+Recv) / Total Assets 35.9% / 33.33% · Interest income / Revenue 0.38% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Evolus, Inc. (EOLS) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
No. Evolus, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.38% of each dividend: Evolus, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.